Publicaciones en las que colabora con Emilio Esteban González (14)

2019

  1. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2018

  1. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  2. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)

    Investigational New Drugs, Vol. 32, Núm. 2, pp. 377-381

2012

  1. Predictive factors for response to treatment in patients with advanced renal cell carcinoma

    Investigational New Drugs, Vol. 30, Núm. 6, pp. 2443-2449

  2. Prognostic factors in patients with advanced renal cell carcinoma

    Clinical Genitourinary Cancer, Vol. 10, Núm. 4, pp. 262-270

2011

  1. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485

2010

  1. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: Study based on experience at the Hospital Universitario Central de Asturias

    Clinical and Translational Oncology, Vol. 12, Núm. 8, pp. 562-567

2009

  1. Intravenous Topotecan in patients with advanced non-small cell lung cancer pre-treated with platinum and taxanes: Results of a phase II study

    EJC SUPPLEMENTS

  2. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine

    Clinical and Translational Oncology, Vol. 11, Núm. 1, pp. 35-40

  3. Outcomes of surveillance in unselected patients with clinical stage I testicular germ cell tumors: results of a single institution series

    EJC SUPPLEMENTS

2001

  1. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: A Phase II multicentric trial

    Cancer, Vol. 92, Núm. 10, pp. 2508-2516